Breaking News, Trials & Filings

Perrigo Receives Tentative FDA Approval

For the generic version Onexton Gel (clindamycin phosphate 1.2% and benzoyl peroxide 3.75%)

Perrigo has received tentative approval from the U.S. Food and Drug Administration for the generic version of Onexton Gel (clindamycin phosphate 1.2% and benzoyl peroxide 3.75%).    Perrigo previously settled litigation with Valeant Pharmaceuticals North America LLC and Dow Pharmaceutical Sciences for the product.    Onexton Gel is a prescription medicine indicated for the topical treatment of acne vulgaris in patients 12 years of age and older. Branded market sales for the last ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters